Company profile
K36 Therapeutics, Inc.
Privately held: no public share price (K36 Therapeutics is a privately held clinical-stage biotech (KTX-1001 for t(4;14) multiple myeloma), most recently closing a $70M Series B in June 2023 with participation from Bristol Myers Squibb among other investors (prnewswire.com). No public listing found. Sources: https://clinicaltrials.gov/study/NCT05651932 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | NSD2 (MMSET/WHSC1)Small molecule | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.